3
|
Shi N, Zhou Y, Liu Y, Zhang R, Jiang X, Ren C, Gao X, Luo L. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy. Front Immunol 2022; 13:1047610. [PMID: 36518768 PMCID: PMC9742559 DOI: 10.3389/fimmu.2022.1047610] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 11/14/2022] [Indexed: 11/29/2022] Open
Abstract
Several clinical studies demonstrate that there exist other immune checkpoints overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte-activation gene 3 (LAG-3) is one of the important immune checkpoint molecules and has been clinically demonstrated to have synergistic anti-tumor effects in combination with PD-1 antibody. In this study, we designed a novel 'knob-in-hole' PD-1/LAG-3 bispecific antibody (BsAb) YG-003D3. In conclusion, the BsAb maintained the similar affinity and thermal stability to the parental antibody, and the BsAb structure can be independent of each other in the process of double-target recognition, and the recognition activity will not be affected. Moreover, the BsAb can not only target PD-1 and LAG-3 on single cell simultaneously, but also bridge the two kinds of cells expressing PD-1 and LAG-3, so as to release the 'brake system of immune checkpoints' and activate immune cells to exert anti-tumor effects more effectively. Especially in the PBMCs activation assay, YG-003D3 induced stronger IFN-γ, IL-6, and TNF-α secretion compared to anti-PD-1 or anti-LAG-3 single drug group or even combined drug group. In the tumor killing experiment of PBMC in vitro, YG-003D3 has a better ability to activate PBMC to kill tumor cells than anti-PD-1 or anti-LAG-3 single drug group or even combined drug group, and the killing rate is as high as 20%. In a humanized PD-1/LAG-3 transgenic mouse subcutaneous tumor-bearing model, YG-003D3 showed good anti-tumor activity, even better than that of the combination group at the same molar concentration. Further studies have shown that YG-003D3 could significantly alter the proportion of immune cells in the tumor microenvironment. In particular, the proportion of CD45+, CD3+ T, CD8+ T cells in tumor tissue and the proportion of CD3+ T, CD8+ T, CD4+ T cells in peripheral blood were significantly increased. These results suggest that YG-003D3 exerts a potent antitumor effect by activating the body 's immune system. In summary, the BsAb YG-003D3 has good anti-tumor activity, which is expected to become a novel drug candidate for cancer immunotherapy.
Collapse
Affiliation(s)
- Ning Shi
- National Health Commission (NHC) Key Laboratory of Carcinogenesis, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China,State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China,Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China,Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, China
| | - Yangyihua Zhou
- State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China,Hunan Normal University School of Medicine, Changsha, Hunan, China
| | - Yujun Liu
- State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China
| | - Ran Zhang
- Hunan Normal University School of Medicine, Changsha, Hunan, China
| | - Xingjun Jiang
- National Health Commission (NHC) Key Laboratory of Carcinogenesis, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China,Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Caiping Ren
- National Health Commission (NHC) Key Laboratory of Carcinogenesis, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China,Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China,Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, China,*Correspondence: Caiping Ren, ; Xiang Gao, ; Longlong Luo,
| | - Xiang Gao
- State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China,*Correspondence: Caiping Ren, ; Xiang Gao, ; Longlong Luo,
| | - Longlong Luo
- State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China,*Correspondence: Caiping Ren, ; Xiang Gao, ; Longlong Luo,
| |
Collapse
|
6
|
Wang Z, Hu N, Li X, Wang H, Ren C, Qiao C, Chen G, Wang J, Zhou L, Wu J, Zhang D, Feng J, Shen B, Peng H, Luo L. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library. Mol Pharmacol 2021; 100:193-202. [PMID: 34315811 DOI: 10.1124/molpharm.120.000202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 06/11/2021] [Indexed: 11/22/2022] Open
Abstract
Phagocytic resistance plays a key role in tumor-mediated immune escape, so phagocytosis immune checkpoints are a potential target for cancer immunotherapy. CD47 is one of the important phagocytosis immune checkpoints; thus, blocking the interaction between CD47 and signal regulatory protein α (SIRPα) may provide new options for cancer treatment. Using computer-aided targeted epitope mammalian cell-displayed antibody library, we screened and obtained an engineered SIRPα variant fragment crystallizable fusion protein, FD164, with higher CD47-binding activity than wild-type SIRPα Compared with wild-type SIRPα, FD164 has approximately 3-fold higher affinity for binding to CD47, which further enhanced its phagocytic effect in vitro and tumor suppressor activity in vivo. FD164 maintains the similar antitumor activity of the clinical research drug Hu5F9 in the mouse xenograft model. Furthermore, FD164 combined with rituximab can significantly improve the effect of single-agent therapy. On the other hand, compared with Hu5F9, FD164 does not cause hemagglutination, and its ability to bind to red blood cells or white blood cells is weaker at the same concentration. Finally, it was confirmed by computer structure prediction and alanine scanning experiments that the N45, E47, 52TEVYVK58, K60, 115EVTELTRE122, and E124 residues of CD47 are important for SIRPα or FD164 recognition. Briefly, we obtained a high-affinity SIRPα variant FD164 with balanced safety and effectiveness. SIGNIFICANCE STATEMENT: Up to now, few clinically marketed drugs targeting CD47 have been determined to be effective and safe. FD164, a potential signal regulatory protein α variant fragment crystallizable protein with balanced safety and effectiveness, could provide a reference for the development of antitumor drugs.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antigens, Differentiation/adverse effects
- Antigens, Differentiation/chemistry
- Antigens, Differentiation/genetics
- Antigens, Differentiation/immunology
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Burkitt Lymphoma/drug therapy
- Burkitt Lymphoma/immunology
- Burkitt Lymphoma/pathology
- CD47 Antigen/chemistry
- CD47 Antigen/immunology
- CHO Cells
- Cell Line
- Cricetulus
- Drug Design
- Epitopes/chemistry
- Epitopes/genetics
- Epitopes/immunology
- Hemagglutination/drug effects
- Immunotherapy
- Mice, SCID
- Models, Molecular
- Phagocytosis/drug effects
- Phagocytosis/immunology
- Receptors, Immunologic/chemistry
- Receptors, Immunologic/genetics
- Receptors, Immunologic/immunology
- Recombinant Fusion Proteins/adverse effects
- Recombinant Fusion Proteins/chemistry
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Rituximab/therapeutic use
- Tumor Burden/drug effects
- Xenograft Model Antitumor Assays
- Mice
Collapse
Affiliation(s)
- Zhihong Wang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Naijing Hu
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Xinying Li
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Haitao Wang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Caiping Ren
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Chunxia Qiao
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Guojiang Chen
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Jing Wang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Liuzhong Zhou
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Jiaguo Wu
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Dingmu Zhang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Jiannan Feng
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Beifen Shen
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Hui Peng
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| | - Longlong Luo
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)
| |
Collapse
|